Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
BioNTech reported a loss of $721 million in 2024, attributed to low demand for COVID-19 vaccines. Despite beating fourth-quarter earnings estimates with a profit of €1.08 per share, surpassing expectations of €0.38, the company experienced a decline from the previous year's earnings of €1.88. Revenue for the fourth quarter reached €1.19 billion, exceeding consensus estimates of €1.09 billion. However, the company's outlook for 2025 has disappointed investors, raising concerns about its future as it faces significant revenue declines and potential job losses for hundreds of employees.
Das Land diskutiert über eine dringend benötigte "#Corona-Aufarbeitung". Uğur Şahin und sein Unternehmen #BioNTech spielen bis dato dabei überraschend weiterhin keinerlei Rolle. Nun verkündet das "Erfolgsunternehmen" aus Mainz massive Umsatzeinbrüche. https://t.co/iiy3memdFf
Conti in rosso alla Biontech, l'azienda di biotecnologie diventata ricca e famosa cinque anni fa per aver sviluppato il primo vaccino efficace contro il covid. Le perdite in bilancio arrivano a 700 milioni e centinaia di dipendenti rischiano il posto https://t.co/USwcNLXNrA
BioNTech beats Q4 estimates but 2025 outlook disappoints 📉💉 BioNTech $BNTX, Pfizer's $PFE COVID-19 vaccine partner, posted Q4 earnings of €1.08 per share, beating expectations (€0.38) but down from last year (€1.88). Revenue hit €1.19B, also above consensus (€1.09B), but… https://t.co/QsFkxuE6X8